Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03202940
Recruitment Status : Recruiting
First Posted : June 29, 2017
Last Update Posted : March 9, 2021
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : November 30, 2024